Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Each year, the global oncology community flocks to Chicago to convene at the American Society of Clinical Oncology’s ann | Each year, the global oncology community descends on Chicago for ASCO, where buzzy data drops, practice-changing posters and packed sessions offer a look at where cancer care is headed next. In this week’s episode of “The Top Line,” Fierce Biotech’s Darren Incorvaia and Fierce Pharma’s Zoey Becker and Angus Liu break down the biggest takeaways from their weekend reporting live from the Windy City, from “nutty” in vivo CAR-T data to a historic first for a Chinese biotech asset.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise

At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways

ASCO 2026: key readouts in lung cancer - Pharmaceutical Technology

ASCO26: Blood cancer readouts take centre stage - Pharmaceutical Technology

A standing ovation for RevMed, and caution for Akeso

ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

There were 487 exhibitor booths at the American Society of Clinical Oncology (ASCO)’s 2026 annual meeting, held in Chicago’s…

A recurring theme at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting wasn’t a single dataset, biomarker, or…

In 2017, a little-known company called Nanjing Legend Biotech walked into the ASCO annual meeting at the 11th hour, dropped a…

This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s…

Here is some of what you may have missed from the world's largest cancer research meeting.

Here's what to watch for at ASCO, cancer research's big meeting, in Chicago.